Extended-Duration Low-Dose Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism
Conditions: Deep Vein Thrombosis; Pulmonary Embolism; Venous Thromboembolism Interventions: Drug: Apixaban 2.5 MG; Drug: Placebo oral tablet Sponsor: Brigham and Women's Hospital Not yet recruiting
CONCLUSION: Thus, diabetes mellitus itself was not an independent factor associated with IAD. A larger IAD was preferentially associated with the presence of PAD, and this association was modified by age. PMID: 31813900 [PubMed - as supplied by publisher]
We report a case of Kounis syndrome type III (coronary thrombosis) variant in a 48-year-old male, who had suffered recurrent acute myocardial infarction after scallion-induced hypersensitivity reactions. Following appropriate anti-thrombotic, anti-histamine and reperfusion strategies, the patient was found to have elevated levels of IgE and chronic urticaria. Upon administration of omalizumab there was an improvement of chronic urticaria, decrease in IgE levels and abolishing of the ischemic attacks.
Conclusion: Sirolimus-eluting Stentys stent may represent a potential solution for specific coronary anatomies such as bifurcation, ectasic, or tapered vessels. Risk of stent thrombosis appears related to clinical presentation with STEMI and to anatomic features, stressing the importance of the use of intracoronary imaging for self-expandable stents implantation.
Conclusions DCB angioplasty for de novo small coronary lesions in the real-world environment in Japan is effective with acceptable 12-month outcomes.
Background We hypothesized that the transition from bare-metal stents (BMS) to newer generation drug-eluting stents (n-DES) in clinical practice may have reduced the risk also in patients with kidney dysfunction. Methods: Observational study in the national SWEDEHEART registry, that compared the 1-year risk of in-stent restenosis (RS) and stent thrombosis (ST) in all percutaneous coronary intervention treated patients(n = 92 994) during 2007–2013. Results: N-DES patients were younger than BMS, but had more often diabetes, previous myocardial infarction, previous revascularization and were more often treated w...
Conclusion Compared with heparin plus GPI or bivalirudin plus GPI, bivalirudin monotherapy provides similar protection from ischemic events with less major bleeding at 30 days among patients with NSTE-ACS and positive biomarkers.
Congenital fibrinogen disorders are rare inherited bleeding disorders characterized by bleeding or thrombosis. They can be divided into type I deficiencies or quantitative defects (afibrinogenemia and hypofibrinogenemia) which are defined when those with fibrinogen levels are below 1.5 g/L and type II deficiencies or qualitative defects (dysfibrinogenemia and hypodysfibrinogenemia) . The estimated prevalence of afibrinogenemia is about 1:1,000,000. Although dysfibrinogenemia and hypofibrinogenemia are more frequent, their accurate prevalence remains unknown as most cases are asymptomatic [1,2].
SummaryPurpose Anticancer agents are known to increase cancer-associated thrombosis (CAT) onset. CAT onset rate is reported to be 1.92% in cisplatin-based therapy, 6.1% in paclitaxel plus ramucirumab combination therapy, and 11.9% in bevacizumab monotherapy. Because immune checkpoint inhibitors (ICIs) cause a sudden increase in T cell number, an association between administration of these drugs and increase in CAT incidence is likely. However, the extent to which ICI administration affects CAT incidence remains unclear. Further, risk factors for CAT incidence have not yet been identified. The present study investigated CAT...
The angiogenesis inhibitor monoclonal antibody Bevacizumab is presently the standard treatment for numerous neoplasms but particular toxicities are emerging, such as hypertension, haemorrhage, thromboembolism,...
Clinical presentation of stent thrombosis (ST) and its sequela under contemporary practice have not been fully elucidated, largely due to rare incidence of ST. We sought to assess the characteristics in patients with clinical presentation of ST and their in-hospital outcomes, utilizing nationwide registration system for percutaneous coronary interventions (J-PCI). The present study included acute coronary syndrome (ACS) patients undergoing PCI with clinical findings of definite ST from January 2014 to December 2016.